AUROPHARMAPharmaceuticals
Aurobindo Pharma Ltd — Cash Flow Statement
₹1304.40
+0.49%
Aurobindo Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash Dividends Paid | -1.04 Cr | -263.64 Cr | -439.53 Cr | -263.70 Cr | — |
| Net Common Stock Issuance | -930.24 Cr | 0.00 | — | — | 0.00 |
| Common Stock Payments | -930.24 Cr | 0.00 | — | — | — |
| Net Issuance Payments Of Debt | 1.60K Cr | 1.46K Cr | 2.46K Cr | -2.55K Cr | — |
| Net Short Term Debt Issuance | 2.06K Cr | -84.76 Cr | 2.07K Cr | -2.64K Cr | — |
| Net Long Term Debt Issuance | -457.43 Cr | 1.55K Cr | 387.93 Cr | 82.73 Cr | — |
| Long Term Debt Payments | -1.12K Cr | -17.17 Cr | -5.65 Cr | 0.00 | — |
| Long Term Debt Issuance | 661.43 Cr | 1.56K Cr | 393.58 Cr | 82.73 Cr | — |
| Investing Cash Flow | -1.88K Cr | -4.26K Cr | -3.98K Cr | -3.21K Cr | — |
| Net Other Investing Changes | 216.77 Cr | -1.19K Cr | -1.66K Cr | 74.93 Cr | — |
| Interest Received Cfi | 347.37 Cr | 280.84 Cr | 146.62 Cr | 25.26 Cr | — |
| Net Investment Purchase And Sale | 88.16 Cr | 153.45 Cr | 337.37 Cr | -363.30 Cr | — |
| Sale Of Investment | 111.18 Cr | 177.04 Cr | 2.35K Cr | 461.65 Cr | — |
| Purchase Of Investment | -23.02 Cr | -23.59 Cr | -2.01K Cr | -824.95 Cr | — |
| Net Business Purchase And Sale | -11.39 Cr | 0.00 | -91.59 Cr | -624.75 Cr | — |
| Purchase Of Business | -11.39 Cr | 0.00 | -196.97 Cr | -654.04 Cr | — |
| Net Intangibles Purchase And Sale | -551.69 Cr | -781.17 Cr | -316.60 Cr | -651.73 Cr | — |
| Purchase Of Intangibles | -551.69 Cr | -781.17 Cr | -316.60 Cr | -651.73 Cr | — |
| Net PPE Purchase And Sale | -1.97K Cr | -2.72K Cr | -2.39K Cr | -1.67K Cr | — |
| Sale Of PPE | 2.84 Cr | 60.28 Cr | 11.09 Cr | 380.94 Cr | — |
| Purchase Of PPE | -1.97K Cr | -2.78K Cr | -2.40K Cr | -2.05K Cr | — |
| Operating Cash Flow | 3.92K Cr | 2.43K Cr | 2.39K Cr | 5.02K Cr | — |
| Taxes Refund Paid | -1.73K Cr | -1.77K Cr | -717.24 Cr | -1.26K Cr | — |
| Change In Working Capital | -1.24K Cr | -1.68K Cr | -1.09K Cr | 1.56K Cr | — |
| Change In Other Current Liabilities | 605.33 Cr | 53.98 Cr | 108.75 Cr | 332.81 Cr | — |
| Change In Other Current Assets | -0.34 Cr | -842.57 Cr | -575.36 Cr | 10.59 Cr | — |
| Change In Payable | -310.89 Cr | 582.84 Cr | 707.65 Cr | 110.65 Cr | — |
| Change In Inventory | -735.49 Cr | -1.30K Cr | -926.70 Cr | 1.50K Cr | — |
| Change In Receivables | -862.08 Cr | -264.19 Cr | -431.07 Cr | -408.29 Cr | — |
| Other Non Cash Items | 75.00 Cr | -27.72 Cr | -29.96 Cr | 12.28 Cr | — |
| Provisionand Write Offof Assets | 18.80 Cr | 23.28 Cr | 52.45 Cr | -6.11 Cr | — |
| Depreciation And Amortization | 1.65K Cr | 1.52K Cr | 1.24K Cr | 1.13K Cr | — |
| Depreciation | 1.65K Cr | 1.52K Cr | 833.29 Cr | 797.86 Cr | — |
| Gain Loss On Investment Securities | -19.82 Cr | -2.80 Cr | -19.14 Cr | -61.10 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 58.71 Cr | -51.14 Cr | 310.46 Cr | 104.97 Cr | — |
| Gain Loss On Sale Of PPE | 8.94 Cr | -23.49 Cr | -13.23 Cr | 135.02 Cr | — |
| Net Income From Continuing Operations | 5.07K Cr | 4.38K Cr | 2.61K Cr | 3.37K Cr | — |
| Free Cash Flow | 1.41K Cr | -1.13K Cr | -333.65 Cr | 2.31K Cr | — |
| Repurchase Of Capital Stock | -930.24 Cr | 0.00 | — | — | — |
| Repayment Of Debt | -1.12K Cr | -17.17 Cr | -5.65 Cr | 0.00 | — |
| Issuance Of Debt | 661.43 Cr | 1.56K Cr | 393.58 Cr | 82.73 Cr | — |
| Capital Expenditure | -2.52K Cr | -3.56K Cr | -2.72K Cr | -2.70K Cr | — |
| End Cash Position | 5.56K Cr | 3.39K Cr | 4.39K Cr | 4.16K Cr | — |
| Other Cash Adjustment Outside Changein Cash | 0.66 Cr | — | 6.41 Cr | -3.25 Cr | 22.41 Cr |
| Beginning Cash Position | 3.39K Cr | 4.39K Cr | 4.16K Cr | 5.33K Cr | — |
| Effect Of Exchange Rate Changes | 9.10 Cr | 14.17 Cr | -0.06 Cr | 0.20 Cr | — |
| Changes In Cash | 2.17K Cr | -1.02K Cr | 223.41 Cr | -1.16K Cr | — |
| Financing Cash Flow | 119.78 Cr | 800.42 Cr | 1.81K Cr | -2.97K Cr | — |
| Net Other Financing Charges | -22.50 Cr | — | — | — | — |
| Interest Paid Cff | -420.32 Cr | -250.65 Cr | -111.20 Cr | -18.50 Cr | — |
| Amortization Cash Flow | — | 573.77 Cr | 411.29 Cr | 328.66 Cr | 253.78 Cr |
| Common Stock Dividend Paid | — | — | -439.53 Cr | -263.70 Cr | — |
| Sale Of Business | — | — | 105.38 Cr | 29.29 Cr | 3.17K Cr |
| Gain Loss On Sale Of Business | — | — | 0.00 | 2.65 Cr | -3.25K Cr |
| Short Term Debt Payments | — | — | — | -2.64K Cr | -667.82 Cr |
| Common Stock Issuance | — | — | — | — | 0.00 |
| Dividends Received Cfi | — | — | — | — | 0.00 |
| Issuance Of Capital Stock | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Aurobindo Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.